Search - tctmd.com

Displaying 141 - 160 of 210

Sort: Relevancy | Date

Massive Study Offers Snapshot of PCI Outcomes in Nonagenarians

News Conference News TCT 2017

Massive Study Offers Snapshot of PCI Outcomes in Nonagenarians

November 06, 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

September 18, 2017

ACT I: Women Reap More Long-term Benefits From Carotid Stenting vs CEA

News Conference News VIVA 2017

ACT I: Women Reap More Long-term Benefits From Carotid Stenting vs CEA

September 15, 2017

VIVA: Could Population-Wide Screening Trial for AAA, PAD, and Hypertension Save Lives at Low Cost?

News Conference News ESC 2017

VIVA: Could Population-Wide Screening Trial for AAA, PAD, and Hypertension Save Lives at Low Cost?

August 28, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

Seeing Is Believing: Experts Predict an Expanded Role for Cardiac CT in Structural Interventions

News Conference News SCCT 2017

Seeing Is Believing: Experts Predict an Expanded Role for Cardiac CT in Structural Interventions

Yael L. Maxwell

July 08, 2017

DISRUPT CAD: Lithoplasty May Modify Dense Calcium in Coronary Lesions Before Stenting

News Conference News EuroPCR 2017

DISRUPT CAD: Lithoplasty May Modify Dense Calcium in Coronary Lesions Before Stenting

Yael L. Maxwell

May 22, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

News Conference News ISET 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

February 17, 2017

Targeted Delivery of Dexamethasone Combats Restenosis in Femoropopliteal Lesions: DANCE Trial

News Conference News ISET 2017

Targeted Delivery of Dexamethasone Combats Restenosis in Femoropopliteal Lesions: DANCE Trial

February 15, 2017

Percutaneous Bypass for Long, Complex SFA Lesions Holds Up Well to 6 Months: DETOUR I Study

News Conference News ISET 2017

Percutaneous Bypass for Long, Complex SFA Lesions Holds Up Well to 6 Months: DETOUR I Study

February 10, 2017

Positive 6-Month Outcomes Seen With Endovascular Therapy for Symptomatic PAD: LIBERTY 360

News Conference News ISET 2017

Positive 6-Month Outcomes Seen With Endovascular Therapy for Symptomatic PAD: LIBERTY 360

February 07, 2017

Underappreciated by Clinicians, Critical Limb Ischemia Has Dire Fallout for Patients

News Conference News ISET 2017

Underappreciated by Clinicians, Critical Limb Ischemia Has Dire Fallout for Patients

February 07, 2017

Routine Screening of ABI to Identify PAD: Despite Guidelines, One Expert Asks Why Not?

News Conference News ISET 2017

Routine Screening of ABI to Identify PAD: Despite Guidelines, One Expert Asks Why Not?

February 06, 2017

News Conference News AHA 2016

AHA/ACC Issue Updated PAD Guidelines

November 14, 2016

News Conference News TCT 2016

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

Michael O'Riordan

October 29, 2016

News Conference News TCT 2016

Transcaval TAVR Presents New Option for Patients With Complex Anatomy

Yael L. Maxwell

October 29, 2016

News Conference News VIVA 2016

Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option

October 12, 2016

News Conference News VIVA 2016

Bioresorbable Scaffold Shows Sustained Promise in Superficial Femoral and Iliac Artery Lesions

September 22, 2016

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

September 21, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.